AWIQLI (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
AWIQLI
Date registered
Evaluation commenced
Decision date
Approval time
193 (255 working days)
Active ingredients
insulin icodec
Registration type
NCE/ NBE
Indication
Treatment of Type 2 Diabetes in adults.
Treatment of Type 1 Diabetes in adults, in conjunction with a bolus insulin, where daily basal insulin injections are not suitable.